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Nephrogenic Systemic Fibrosis
Pathogenesis, Diagnosis, and Therapy
Andreas Kribben, MD,* Oliver Witzke, MD,* Uwe Hillen, MD,† Jörg Barkhausen, MD,‡
Anton E. Daul, MD, Raimund Erbel, MD§
Essen, Germany
Nephrogenic systemic fibrosis (NSF) is a newly recognized disorder occurring exclusively in patients with renal
failure. Exposure to gadolinium-based magnetic resonance (MR) contrast media has been associated with subse-
quent development of NSF. Nephrogenic systemic fibrosis is characterized by skin induration preferentially af-
fecting the extremities. In addition, involvement of internal organs occurs, which leads ultimately to death. Skin
biopsy is important for confirmation of the diagnosis. The main therapeutic goal is restoration of renal function.
To reduce the risk of NSF, renal function must be determined before exposure to gadolinium-containing MR con-
trast agents. Gadolinium-based MR contrast media should be avoided in the presence of advanced renal failure
with estimated glomerular filtration rate below 30 ml/min/1.73 m2, unless the diagnostic information is essen-
tial and not available with noncontrast magnetic resonance imaging techniques. The recommended dose of con-
trast agent should not be exceeded. In addition, a sufficient period of time for elimination of the contrast agent
from the body should be allowed before readministration of the contrast agent. (J Am Coll Cardiol 2009;53:
1621–8) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.061E
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pephrogenic systemic fibrosis (NSF) is a new disorder
xclusively observed in patients suffering from renal failure.
ecause it was initially assumed that the disorder was
imited to the skin, the term “nephrogenic fibrosing der-
atopathy” was chosen (1). The recognition of the disor-
er’s systemic nature with fibrotic changes in various organ
ystems led to the renaming of the disease as nephrogenic
ystemic fibrosis (2). As of May 2008, 215 cases have been
escribed in a U.S. registry (3). Approximately 80 cases are
umulatively reported within European patients; the reports
ainly originated from Austria and Denmark. A registry for
ermany was opened in the summer of 2007 (4). Gadolinium-
ontaining magnetic resonance (MR) contrast agents seem
o be associated with the disease development (5,6). This
verview summarizes the current knowledge about the
athogenesis, diagnosis, and therapy in order to increase
wareness of this new syndrome.
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rom Bayer Schering AG and GE Healthcare Buchler (Amersham). Dr. Barkhausen
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008, accepted December 8, 2008.pidemiology
ephrogenic systemic fibrosis was only recognized after
arge numbers of patients were given gadolinium-based
ontrast agents. Before 1997 the disease was not reported.
here was a change in clinical practice and use of high-dose
adolinium-enhanced magnetic resonance angiography (MRA)
or improved imaging. Gadolinium-enforced MRA was
sed preferentially in patients with renal failure to avoid
odinated (X-ray) contrast agents. The increasing cumula-
ive dosage of these gadolinium-containing contrast agents
ight have contributed to the development of NSF. Nev-
rtheless, the combination of rapid, higher-than-approved
oses of contrast agents and the clustering of cases were
robably important factors that likely led to the recognition
f this new syndrome.
Additional unknown risk factors might play a role in
acilitating NSF. Nephrogenic systemic fibrosis is diagnosed
ith equal frequency in men and women and affects patients
f all ages and ethnicities (7–9). In a cohort of American
ialysis patients, the frequency was 3 cases in 467 patients
bserved over 18 months, resulting in an estimation of 4.3
ases/1,000 patient-years (10). The risk of triggering the
isorder in these patients through a gadolinium application
ith different gadolinium-based agents was calculated to be
.4% (10).
A recent European study found NSF in 18 (18%) of 102
atients with stage 5 chronic kidney disease (CKD) with
nd without dialysis after exposure to the gadolinium
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Nephrogenic Systemic Fibrosis May 5, 2009:1621–8derivate gadodiamide (Omnis-
can, GE Healthcare Medical Di-
agnostics, Amersham, United
Kingdom). Most of the patients
in this study received high doses
of gadodiamide (typically approxi-
mately 0.3 mmol/kg) for angiogra-
phy (11). Another study using
Gadoteridol (ProHance, Bracco
Diagnostics, Milan, Italy) in 141
patients receiving long-term he-
modialysis found no NSF (12). A
further study found discrete clin-
ical signs of NSF in 30% of
hemodialysis patients after gado-
pentetate dimeglumine (Magnev-
ist, Bayer Schering Pharma AG,
erlin, Germany) exposure. However, skin biopsies were
ot used to confirm the diagnosis of NSF in this patient
ohort (13). Prince et al. (14) assessed the incidence of NSF
n 2 large medical centers in the U.S. Of 83,121 patients
ho received gadolinium-based contrast agents, 15 (0.02%)
eveloped NSF. All of them got a high dose of the contrast
gent that exceeded the standard dosage. Most of them
uffered from acute renal failure at the time of administra-
ion; 8.4% of all patients with acute renal failure receiving
adolinium developed NSF. Wertman et al. (15) recently
alculated the benchmark incidence of NSF with data from
large U.S. health care centers. The benchmark incidence
f NSF ranged from 1 of 2,131 patients to 1 of 65,000
atients. This study confirmed previous findings showing
hat only patients with severe renal impairment and/or stage
/5 CKD develop NSF.
enal failure
ccording to current knowledge, impaired renal function
eems to be a conditio sine qua non for NSF. Nephrogenic
ystemic fibrosis was described in patients with stage 4 and
CKD without dialysis, patients requiring dialysis (hemo-
ialysis and peritoneal dialysis), patients who had received
enal transplants, as well as patients with acute kidney injury
AKI).
CKD is defined as either kidney damage or glomerular
ltration rate (GFR) 60 ml/min/1.73 m2 for 3 months.
idney damage is defined as pathologic abnormalities or
arkers of damage, including abnormalities in blood or
rine tests or imaging studies (16). Chronic kidney disease
s classified into 5 stages according to the GFR. Stage 1
KD is diagnosed as kidney damage with normal or
ncreased GFR (90 ml/min/1.73 m2); stage 2 is diagnosed
s kidney damage with a GFR of 60 to 89 ml/min/1.73 m2.
tage 3 CKD is defined by a GFR of 30 to 59 ml/min/1.73
2, and stage 4 CKD is defined by a GFR of 15 to 29
Abbreviations
and Acronyms
AKI  acute kidney injury
CKD  chronic kidney
disease
FDA  Food and Drug
Administration
GFR  glomerular filtration
rate
MRA  magnetic
resonance angiography
MRI  magnetic resonance
imaging
NSF  nephrogenic
systemic fibrosisl/min/1.73 m2. Stage 5 CKD is defined as established gidney failure with a GFR 15 ml/min/1.73 m2 or perma-
ent dialysis therapy (16).
The extent of renal failure that triggers NSF is not
nown. There are only a few cases with a GFR 15
l/min/1.73 m2 reported. To the authors’ best knowledge,
here is no case with a reported GFR 30 ml/min/1.73 m2.
lthough severe renal impairment seems to be a major
ondition, caution should be advised in recommending a
afe range for gadolinium exposure above a specific GFR
ntil further details of the disease are elucidated.
adolinium exposure
he association between the occurrence of NSF and pre-
eding gadolinium exposure within the context of an MR
tudy was first demonstrated in 2006 by Grobner (5) and his
eam in Austria in 5 patients and by Marckman et al. (6) in
9 patients from Denmark. An evaluation of an American
atient cohort indicated gadolinium exposure for patients
efore the manifestation of NSF. Gadolinium was found in
he skin of the patients (17,18). This association led to
arnings by the Food and Drug Administration (FDA) and
he European Agency for the Evaluation of Medicinal
roducts regarding the use of gadolinium-containing con-
rast agents in patients suffering from renal failure (19,20).
In normal renal function, free gadolinium is removed by
he kidney with a half-life of approximately 2 hours. In
mpaired renal function, this half-life is significantly longer.
wo consecutive hemodialysis sessions remove approxi-
ately 93% of the gadolinium, whereas the peritoneal dialysis
s significantly less effectively and only removes approximately
5% of the gadolinium after 5 days (21–23).
A recent meta-analysis by Agarwal et al. (24) demon-
trated a significant association between gadolinium-based
ontrast agent exposure and NSF. Nevertheless, at the time
f this writing it cannot be decided whether or not the risk
f occurrence of NSF differs for the various gadolinium-
ontaining contrast agents (Table 1). The majority of patients
ith NSF cases had a prior administration of gadodiamide
Omniscan, GE Healthcare Medical Diagnostics), although
he product is used in only approximately 15% of magnetic
esonance imaging (MRI) studies worldwide (25). It has
een hypothesized that the occurrence of NSF after the
pplication of gadodiamide is related to the lower stability
nd increased occurrence of toxic free gadolinium in the gadodia-
ide complex (26,27). Nevertheless, in some of the studies
he gadodiamide dose was very high; thus it has to be
onsidered that the high dosage rather than gadodiamide
tself facilitated the development of NSF in these cases
5,6,28–31). According to the FDA, no MR contrast agent
an principally be regarded as safe, because NSF has also
een observed after exposure to other gadolinium-
ontaining contrast agents in the U.S. (19): Gadopentetane
imeglumin (Magnevist, Bayer Schering Pharma AG),
adobenate dimeglumin (MultiHance, Bracco Diagnostics),
adodiamide (Omniscan, GE Healthcare Medical Diagnos-
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May 5, 2009:1621–8 Nephrogenic Systemic Fibrosisics), gadoversatemide (Optimark, Mallinckrodt, St. Louis,
issouri), and gadoteridol (ProHance, Bracco Diagnos-
ics). However, in some patients, coadministration of gado-
enate dimeglumin (MultiHance, Bracco Diagnostics) and
adodiamide had been described (27). Nephrogenic sys-
emic fibroses have been reported after administration of
adoterate meglumin (Dotarem, Guerbet SA, Aulnay-sur-
ois, France), gadobutrol (Gadovist, Bayer Schering
harma AG), gadoxet acid dinatrium (Primovist, Bayer
chering Pharma AG), or gadofosveset trinatrium (Vaso-
ist, Bayer Schering Pharma AG) (Table 1). But, the
epeated gadolinium exposures seems to increase the risk of
SF by 5- to 10-fold as compared with single gadolinium
xposure (32).
athogenesis
he mechanisms of gadolinium-related damage to the skin
nd other organs are not well-understood (5,6,33). Gado-
inium deposits are found in the skin of NSF patients, which
mplies a direct toxic effect of gadolinium (17,18). Gado-
inium can block ion channels in an unspecific way. This
ffect, however, has mainly been shown in epithelial cells
34). In addition, gadolinium chelates undergo transmetal-
ation in vivo (33). This might be triggered by elevation in
ree serum iron after gadolinium exposure. Exogenous iron
reatment and chronic microinflammation in renal failure
ave been suggested to contribute to free gadolinium release
33). Iron induces transmetallation of gadolinium chelates
35). The combination of free gadolinium and the toxic
ffects of iron might result in initial tissue injury, especially
nder conditions of inflammation and oxidative stress in
atients with renal failure.
It is currently unclear what types of fibroblasts contribute
o the development of NSF. Cowper and Bucala (36)
uggested that spindle cells seen in skin biopsies of NSF
atients are derived from circulating fibrocytes, because
hese cells show CD34 and procollagen 1 expression. Why
hese cells seem to be persistently activated after the initial
rigger is removed is currently unclear. Moreover, further
adolinium Chelates for Use in Magnetic Resonance Imaging
Table 1 Gadolinium Chelates for Use in Magnetic Resonance Im
Generic Name Brand Name Chemical Structure C
Gadodiamide Omniscan Linear No
Gadoversetamide OptiMARK Linear No
Gadopentetic acid Magnevist Linear Ion
Gadobenic acid MultiHance Linear Ion
Gadoxetic acid Primovist Linear Ion
Gadofosveset Vasovist Linear Ion
Gadoteridol ProHance Cyclic No
Gadobutrol Gadovist Cyclic No
Gadoterat Dotarem Cyclic Ion
ptiMARK is not yet licensed in Europe, whereas several other compounds are not approved by th
EMEA  European Agency for the Evaluation of Medicinal Products.nalysis revealed metal deposition and accumulation in tbrotic areas of vessels. This might contribute to vascular
tiffening and subsequent cardiovascular events.
The use of high doses of erythropoiesis-stimulating
gents seems to be associated with NSF due to vascular
njury and endothelial dysfunction with subsequent devel-
pment of fibrogenesis (6,33,37). Furthermore, erythropoi-
tin as well as parathyroid hormone induces the systemic
elease of CD34 cells that are involved in the fibrotic
rocess of wound-healing (38,39).
ssociation with thrombophilia. A significant number of
atients showed acute thromboses or coagulation abnormal-
ties (2,8). These patients had occlusion of the hemodialysis
ccess routes shortly before the manifestation of the NSF.
his involved both native vessels and implanted dialysis
atheters or artificial arteriovenous grafts. Deep vein throm-
osis as well as renal vein and vena cava thrombosis have
een observed in association with the subsequent develop-
ent of NSF (40–42). Some patients had auto-antibodies
o cardiolipin (43). The link of NSF to thrombosis might
ndicate an inflammatory genesis as a co-factor for the
evelopment of NSF (8,44).
ssociation with surgical procedures. Surgical proce-
ures, particularly those with the placement of a blood vessel
ccess for hemodialysis, have been associated with the
evelopment of NSF. If organ transplantation and the
lacement of central catheters are included, approximately
0% of the NSF patients reported such an event shortly
efore the start of symptoms. The perioperative activation
f the coagulation and the inflammation might be respon-
ible for this reaction (8,30).
ssociation with liver disease. Some patients with NSF
how chronic liver disease, including chronic hepatitis B or
(8,30). There has also been an association between NSF
nd hepatorenal-syndrome or the peri-transplant period
fter liver transplantation (28).
iagnosis: Symptoms and Findings
linical presentation. The cutaneous lesions of NSF are
istributed symmetrically over the limbs and the trunk.
nvolvement of the legs frequently extends upward from the
g
Elimination Protein Binding Approving Body
Renal None FDA EMEA
Renal None FDA
Renal None FDA EMEA
97% renal, 3% bile 5% FDA EMEA
50% renal, 50% bile 15% EMEA
91% renal, 9% bile 85% EMEA
Renal None FDA EMEA
Renal None EMEA
Renal None EMEA
and Drug Administration (FDA) but are available in Europe.agin
harge
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icalocalcanean joints to the center of the thighs; on the arms,
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Nephrogenic Systemic Fibrosis May 5, 2009:1621–8nvolvement extends from the wrist to the center of the
pper arm. The primary efflorescences consist of coarse skin
ith or without erythematous papules that might form a
onfluence of brown, indurated cobblestone-like plaques
Fig. 1). The lesions might possess a peau d=orange aspect.
welling of the arms and legs is occasionally observed
Fig. 2). The palpatory indurated areas might have a
ood-like texture. Because the skin lesions frequently ex-
end beyond the joints, restriction of movement ranging
hrough to contraction might develop, even within days or
eeks. The patients complain about pain or itchiness in the
ffected skin areas (8).
Subtle cutaneous changes, defined as hyperpigmentation,
nd hardening and tethering of the skin are found in 30% of
emodialysis patients after gadolinium (gadopentetate dimeglu-
ine) exposure. These changes are associated with a signif-
cantly increased risk of mortality as compared with a
emodialysis cohort without cutaneous involvement (13). A
coring system was proposed assessing hyperpigmentation
comparing appearance of the skin on the extremities with
kin elsewhere), hardening (by gradually applying increasing
Figure 1 Typical Cutaneous Lesions on a Leg
of a 78-Year-Old Male Patient With NSF
Typical cutaneous lesions on a leg of a 78-year-old male patient with nephro-
genic systemic fibrosis (NSF) showing coarse skin and erythematous papules
and confluent brown indurated cobblestone-like plaques. The NSF developed in
this patient approximately 2 months after application of 2 doses of gadodia-
mide (cumulative dose: 41 mmol). Both arms and legs were affected, and the
lateral thoracic wall was involved.
Figure 2 Swelling of the Arm Extending From the Wrist to the
of the Upper Arm in the Same 78-Year-Old Male Patie
A biopsy was taken and examined. Within the dermis, proliferating fibroblasts and
moreover, an inflammatory mononuclear cell infiltrate consisting of lymphocytes anressure while palpating the skin on the extremities in a
ircular motion), and tethering (resistance to motion while
ently pinching the skin). A binary value of either 0 or 1 was
ssigned for these 3 characteristics, and a score of 2 and 3
as defined for clinical evidence of NSF (13). The validity
f this approach and its comparison with histological data
eed to be explored by further studies.
Apart from the skin involvement, the skeletal muscle and
he visceral muscle of the gastrointestinal tract (esophagus,
tomach) and the cardiac muscles seem to be affected. In 1
tudy, the amount of cardiac gadolinium deposits was
hown to be as high as in affected skin (45). In addition,
ardiac fibrosis was revealed in 1 case with gadolinium
eposits of the heart. This study also demonstrated gado-
inium, iron, and aluminum accumulation in the blood
essels and skin of these patients. Moreover, the authors
eported that a form of accelerated cardiovascular disease
as found in patients who died after the onset of NSF (45);
evertheless, due to the design of the study, it cannot be
oncluded that this association is of causal type. Fibrosis of
erous membranes, including the meninges, might also
ccur (40–42). Involvement of the eyes with scleral plaques
as also been reported (46).
aboratory findings. The most significant laboratory find-
ngs in patients with NSF consist of impaired renal func-
ion. Other factors described in NSF, like cardiolipin
ntibodies, antinuclear antibodies, and elevated calcium and
hosphate concentrations, are not specific (8).
kin and tissue biopsies. The diagnosis of NSF is con-
rmed by means of a skin biopsy (33,41,42,45). It is
mportant to take a sufficiently large and deep biopsy
including subcutaneous fat). Histopathologic findings de-
end on the point of time in the course of disease in which
he biopsy is taken. Fully developed lesions show a cell-rich
ermal fibrosis that might extend to the subcutis. Collagen
undles are thickened and separated from one another by
lefts and interposed thin collagen bundles. The cellular
nfiltrate consists of CD34-positive spindle cells and
r
ith NSF
roblasts were found;
8-expressing cells was detected. NSF  nephrogenic systemic fibrosis.Cente
nt W
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May 5, 2009:1621–8 Nephrogenic Systemic Fibrosisrocollagen-I producing cells with a stellate or epitheloid
ppearance (47). In addition, factor XIIIa-positive cells as
ell as CD68-positive multinuclear macrophages can be
bserved. The immunohistopathological profile leads to the
ypothesis that the cells are circulating fibrocytes, a cell
opulation that originates from the bone marrow and seems
o play a role in wound-healing processes. Skin biopsy
esults are not specific and therefore have to be correlated
ith the clinical presentation. Thus, clinical information
iven to the dermatopathologist should include renal failure
nd gadolinium exposure before the start of the disease (48).
here are also characteristic histopathological changes in
he affected muscle. These are particularly visible in areas
hat are directly below affected skin segments. In regions
ithin clinically healthy skin, no changes are generally
ound, so that the muscle participation is closely linked to
kin involvement. Myopathic changes are frequently diag-
osed in the patient cohort; however, they seem more likely
o represent secondary signs of uraemic neuropathy (8,49).
maging studies. So far, imaging diagnostics have no clear
alue in making the diagnosis and in assessing the progres-
ion of NSF, because the findings are nonspecific (2,8).
ifferential diagnosis. The differential diagnosis of NSF
ncludes a series of other fibrosing skin disorders that can be
linically and histologically differentiated. Scleromyxoedema
hows a different distribution pattern (inclusion of the face
nd neck as well as, frequently, paraproteinemia). Systemic
clerosis might resemble NSF in affecting the extremities
nd the trunk, but it often also involves the face and might
e discriminated from NSF serologically (by the presence of
utoantibodies) and histopathologically. Other differential
iagnoses such as pretibial myxoedema in Basedow’s Dis-
ase or eosinophilic fasciitis are clearly delimitable clinically
nd/or by immunohistology (50).
herapy
verall, there are currently no sufficient data available for
ecommendation of an effective therapy. Restoration of
ufficient renal function is the primary goal when NSF is
dentified (51). This goal might be reached by recovery from
KI or by renal transplantation. Renal transplantation is
ot a well-assessed therapeutic option in NSF. Although a
ecent publication reported clinical improvement of patients
ith NSF after renal transplantation, there are only single
ase reports available and not all patients benefited from
enal transplantation after NSF was diagnosed (8,32,
1–56). Thus, the value of renal transplantation has to be
urther elucidated; there is not enough evidence for a clear
onclusion or recommendation at present (32,51–55). In
ddition, physical therapy and pain management particu-
arly for prophylaxis and therapy of joint contractures is the
ainstay of therapy in NSF. Further therapy attempts were
ade with systemic corticosteroids, thalidomide, pen-
oxyphyllin, intravenous immunoglobulin, plasmapheresis
nd cyclophosphamide, and the chelating agent sodium
M
Nhiosulfate. Overall, improvements were only anecdotally
uccessful, so that no clear recommendations can be given
8,33). Extracorporeal photopheresis has been studied in 7
mall studies with 1 to 5 patients reporting improvements of
kin symptoms, implying that this relatively safe therapy
ight be a good initial treatment option (8,52,57).
onsiderations for the use of gadolinium-containing con-
rast agents in patients with impaired renal function. The
DA has reported that exposure to gadolinium-containing
ontrast agents increases the risk for NSF in patients with
evere acute or chronic renal failure with a GFR below 30
l/min/1.73 m2 and in patients with hepatorenal-syndrome
r in the perioperative liver transplantation period. The
DA ordered Black Box warnings in 2007 suggesting that
ll gadolinium contrast media available in the U.S. might be
inked to NSF and that gadolinium-based magnetic reso-
ance contrast media should be avoided in the presence of
dvanced renal failure with estimated GFR below 30 ml/
in/1.73 m2, unless the diagnostic information is essential
nd not available with other imaging techniques (Table 2)
19). European regulatory recommendations are slightly
ifferent: the Danish Medicines Agencies and the United
ingdom Medicines and Healthcare products Regulatory
ecommendations on the Use of GCCAs
Table 2 Recommendations on the Use of GCCAs
Agency
(Ref. #) Recommendation
ACR (61) ● “If MRI contrast media administration is absolutely
essential. . .[in patients with stage 4 or 5 CKD (eGFR 30 ml/
min/1.73 m2)]. . .judicious use of the lowest possible
doses. . .is probably safest.”
● There is no proof that any gadolinium-based contrast media is
completely safe in this patient group. . .”
FDA (19) ● “. . .Exposure to GBCAs increases the risk for NSF in patients
with:
Œ Acute or chronic severe renal insufficiency (GFR 30 ml/
min/1.73 m2), or
Œ Acute renal insufficiency of any severity due to the hepato-
renal syndrome or in the perioperative liver transplantation
period. . .”
● “. . .NSF is a debilitating and sometimes fatal disease affecting
the skin, muscle, and internal organs. . .”
● “. . .Avoid using a GBCA in patients with known risks for
developing NSF unless the diagnostic information is essential
and cannot be obtained with noncontrast enhanced MRI or
other diagnostic procedures. . .”
● “. . .Screen all patients for renal dysfunction by obtaining a
history and/or laboratory tests. . .”
● “. . .When administering a GBCA, do not exceed the dose
recommended in product labeling. Allow sufficient time for
elimination of the GBCA before any readministration. . .”
MHRA (58) ● “. . .Patients with severe renal impairment (i.e., GFR 30 ml/
min/1.73 m2) should not be given Omniscan or Magnevist. . .”
● “. . .These agents should be used with caution in patients with
moderate renal impairment (i.e., GFR 30 to 59 ml/min/
1.73 m2). . .”
● “. . .Omniscan and Magnevist should be used with caution in
neonates and infants up to age 1 year because of their
immature renal function. . .”
CR  American College of Radiology; AKI  acute kidney injury; CKD  chronic kidney disease;
DA  Food and Drug Administration; GBCA  gadolinium-based contrast agent; GFR  glomer-
lar filtration rate; eGFR  estimated glomerular filtration rate; MHRA  United Kingdom
edicines and Healthcare products Regulatory Agency; MRI  magnetic resonance imaging;
SF  nephrogenic systemic fibrosis.
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Nephrogenic Systemic Fibrosis May 5, 2009:1621–8gency focus on gadodiamide, because this agent is associ-
ted with the highest number of NSF patients. In view of
he Danish Medicines Agencies and the United Kingdom
edicines and Healthcare products Regulatory Agency,
adodiamide is contraindicated in patients with a GFR30
l/min/1.73 m2 (Table 2) (58,59). The American College
f Radiology recommends using gadolinium-based contrast
gents in patients with a GFR 30 ml/min/1.73 m2 only if
t is absolutely essential; the lowest possible dose has to be
dministered (Table 2) (60,61). The American College of
adiology also stressed that no gadolinium-based contrast
gents can be regarded as safe (61).
In Germany, the manufacturer of gadodiamide recom-
ends that this product should not be used in patients with
n impaired GFR of 30 ml/min/1.73 m2 (62). Mean-
hile, such recommendation has also been issued for gado-
entetane dimeglumin (Magnevist, Bayer Schering Pharma
G) (62). Therefore, renal function should be determined
y history and/or laboratory tests before administering
adolinium-containing MR contrast agents. The GFR should
e assessed by measuring creatinine clearance or by means of
he abbreviated Modification of Diet in Renal Disease
ormula. However, in case of acute renal failure, renal
unction cannot be determined by the Modification of Diet
n Renal Disease formula, because creatinine is not in steady
tate. (16).
lternatives to gadolinium-based MRI studies. For all
atients at risk, it must be determined whether the diag-
ostic information can be obtained without the administra-
ion of contrast. There are several alternatives to contrast-
nhanced 3-dimensional MRA for vascular application. Time
f flight and phase contrast MRA introduced more than 20
ears ago have almost completely been replaced by contrast-
nhanced 3-dimensional MRA but still allow visualization
f vascular pathologies (e.g., carotid artery stenoses). Re-
ently, new techniques have been introduced for non-
ontrast MRA of different vascular territories. Steady state
ree precession sequences can be applied for the assessment
f the aorta (63,64), the renal arteries (65), as well as the
oronary arteries (66). Additionally, new techniques have
een introduced to cover a large field of view required for
eripheral MRA (67). In some applications, ultrasound
ight be an alternative in selected patients with renal
ailure. However, ultrasound contrast microbubbles have
any limitations in patients with different types of cardiac
isease, and they are contraindicated in pregnancy and in
ediatrics (68). Contrast enhanced computed tomography
ould be a viable alternative in patients with renal failure.
he nephrotoxicity of iodine contrast media has to be taken
nto account (69,70).
trategies for prevention of NSF in high-risk patients
ith gadolinium exposure. If gadolinium-containing con-
rast agents are to be used in patients with stage 5 CKD or
KI, one of the most controversial issues is the need for
emodialysis after gadolinium exposition. Currently there
dre no data supporting any of the following recommenda-
ions. However, if hemodialysis after gadolinium exposure
as a role, it seems logical to remove as much gadolinium as
oon as possible after exposure. The FDA and the American
ollege of Radiology recommend considering “prompt
emodialysis” and hemodialysis “no later than 2 hours” after
adolinium exposure (Table 2) (19,60). Two hemodialysis
essions that are performed on the following days could
emove approximately 93% of the injected gadolinium (23).
ecause elimination of the gadolinium via peritoneal dial-
sis is considerably lower than via hemodialysis (21), it is
easonable to perform hemodialysis procedures after gado-
inium exposure in peritoneal dialysis patients (71). Because
xogenous iron therapy and application of ESA has been
uggested to contribute to the development of NSF (33,37),
t might be reasonable to suspend medication with these
gents before gadolinium application.
In patients with stage 4 CKD, the discussion about the
se of gadolinium-containing contrast agents is currently
nderway and far from being completed, due to insuffi-
ient data (7,71,72). For the time being, gadolinium-
ontaining contrast agent should only be used in patients
uffering from stage 4 CKD with a strict indication and
fter obtaining written informed consent. Dialysis after
adolinium exposure in these patients does not seem to
e indicated, due to the high morbidity associated with
lacement of a large lumen dialysis catheter (73). The
pplied quantity of gadolinium-containing contrast agent
hould be kept as low as possible in all patients with renal
ailure, and repeated examinations should be avoided. In
lanning the MR examination, several organs and body
egions should be examined with a single application of
he contrast agent.
onsequences for Clinical Work and Practice
NSF is a potentially lethal systemic disorder that fre-
quently manifests itself on the skin in its initial stages.
Nephrogenic systemic fibrosis is observed in patients suf-
fering from renal failure after exposure with gadolinium-
containing MR contrast agents.
Renal function should be determined by history and/or
laboratory tests before administering gadolinium-containing
MR contrast agents. Strict indication for MRI is necessary in
the presence of advanced renal failure.
In patients with stage 4 or 5 CKD, contrast-free MRI
has to be used when possible.
Skin biopsies can be used for confirmation of the diagnosis.
There is no established therapy for NSF.
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